Ultrasensitive CCL2 Detection in Urine for Diabetic Nephropathy Diagnosis Using a WS<sub>2</sub>-Based Plasmonic Biosensor.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38625005.
- Also identified by DOI 10.1021/acs.nanolett.4c00981.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The accurate diagnosis of diabetic nephropathy relies on achieving ultrasensitive biosensing for biomarker detection. However, existing biosensors face challenges such as poor sensitivity, complexity, time-consuming procedures, and high assay costs. To address these limitations, we report a WS<sub>2</sub>-based plasmonic biosensor for the ultrasensitive detection of biomarker candidates in clinical human urine samples associated with diabetic nephropathy. Leveraging plasmonic-based electrochemical impedance microscopy (P-EIM) imaging, we observed a remarkable charge sensitivity in monolayer WS<sub>2</sub> single crystals. Our biosensor exhibits an exceptionally low detection limit (0.201 ag/mL) and remarkable selectivity in detecting CC chemokine ligand 2 (CCL2) protein biomarkers, outperforming conventional techniques such as ELISA. This work represents a breakthrough in traditional protein sensors, providing a direction and materials foundation for developing ultrasensitive sensors tailored to clinical applications for biomarker sensing.
Medical subject headings
- Diabetic Nephropathies
- Biosensing Techniques
- Chemokine CCL2
- Biomarkers